The Journal of Neuropsychiatry and Clinical Neurosciences
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Vlassenko, A.
* Articles by Mintun, M. A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Vlassenko, A.
* Articles by Mintun, M. A.
Related Collections
* Neurophysiology
* Depression
J Neuropsychiatry Clin Neurosci 16:360-363, August 2004
© 2004 American Psychiatric Press, Inc.


Clinical and Research Reports

Cerebral Perfusion Response to Successful Treatment of Depression With Different Serotoninergic Agents

Andrei Vlassenko, M.D., Ph.D., Yvette I. Sheline, M.D., Keith Fischer, M.D. and Mark A. Mintun, M.D.

Received September 18, 2002; revised December 15, 2002; accepted January 13, 2003. From the Department of Radiology, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri. Correspondence and reprints: Dr. Sheline, Associate Professor of Psychiatry and Radiology, Box 8134, WUSM 4940 Childrens Place St. Louis, MO 63110. E-mail: yvette{at}npg.wustl.edu

ABSTRACT

In 19 patients with major depressive disorder, effective treatment with selective serotonin reuptake inhibitors (SSRIs) or amesergide (AMSG) was associated with increased cerebral perfusion in anterior cingulate cortex (SSRI and AMSG) and in medial prefrontal cortex (AMSG). Both selective serotonin reuptake inhibitors and AMSG exert antidepressant action through the serotonin (5-HT) system as reuptake inhibitors. Amesergide differs from SSRIs in that it is also a highly selective 5-HT antagonist, which may in part account for differences in cerebral blood flow response to treatment.




This article has been cited by other articles:


Home page
JNMHome page
Y. Kohn, N. Freedman, H. Lester, Y. Krausz, R. Chisin, B. Lerer, and O. Bonne
99mTc-HMPAO SPECT Study of Cerebral Perfusion After Treatment with Medication and Electroconvulsive Therapy in Major Depression
J. Nucl. Med., August 1, 2007; 48(8): 1273 - 1278.
[Abstract] [Full Text] [PDF]


Home page
Schizophr BullHome page
M. L. Phillips and E. Vieta
Identifying Functional Neuroimaging Biomarkers of Bipolar Disorder: Toward DSM-V
Schizophr Bull, July 1, 2007; 33(4): 893 - 904.
[Abstract] [Full Text] [PDF]


Home page
J. Neuropsychiatry Clin. Neurosi.Home page
L. J. Julian and D. C. Mohr
Cognitive Predictors of Response to Treatment for Depression in Multiple Sclerosis
J Neuropsychiatry Clin Neurosci, August 1, 2006; 18(3): 356 - 363.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2004 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Neuropsychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org